Ready to press play on 'The Matrix Reloaded' right from your couch? Here are platforms and services with rental, purchase, and subscription options, so you can pick what works best for you. 'The ...

Pedro Barata is joined by Kathryn Beckermann to discuss the KEYMAKER-U03 trial. This phase I/II umbrella platform study evaluates combinations in refractory clear-cell kidney cancer patients who ...

The right gear can make all the difference in Marathon. And if you know how the Armory refresh system works, you’ll always have easy access to meds, shields, weapons, and more. Here are all the ...

Investigators sought to determine if adding favezelimab or vibostolimab to enfortumab vedotin/pembrolizumab improved overall response rates in patients with locally advanced or metastatic carcinoma.

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

First-line triplet therapy may expand clinical benefit for advanced clear cell renal cell carcinoma (ccRCC). The phase Ib/II KEYMAKER-U03 Substudy 03A (NCT04626479) investigated novel pembrolizumab ...

Belzutifan, pembrolizumab, and lenvatinib combination showed improved efficacy in advanced ccRCC compared with other regimens. Arm 4 demonstrated a significant median duration of response and ...

Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. Arm 4 demonstrated a median ...